Effects of granulocyte-macrophage colony-stimulating factor on wound contraction.
The effect of topical recombinant murine and human GM-CSF, 1 or 10 micrograms/cm2 for one to ten days, on the contraction and healing of acute and chronic granulating wounds infected with Escherichia coli was studied in Sprague-Dawley rats. Bacterial contamination of wounds produced significant inhibition of wound contraction. Application of GM-CSF at either dose level to infected wounds markedly increased the rate of wound closure compared to the rate in infected untreated controls. Ten days treatment was found to be more effective than a single application. An advanced stage of wound healing was observed at ten days in the GM-CSF-treated rats compared with controls. Bacterial counts decreased in the GM-CSF-treated wounds which may suggest bactericidal activity. Topical treatment with GM-CSF was shown to effectively inhibit the retardation of wound closure produced by bacterial contamination and may therefore be useful in the management of patients with infected wounds.
Robson
M
M
Department of Surgery, Shriner Burns Unit, University of Texas Medical Branch, Galveston.
Kucukcelebi
A
A
Carp
S S
SS
Hayward
P G
PG
Hui
P S
PS
Cowan
W T
WT
Ko
F
F
Cooper
D M
DM
D000287:Administration, Topical; D000704:Analysis of Variance; D000818:Animals; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000188:drug therapy*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D014945:Wound Healing / Q000187:drug effects*; D014946:Wound Infection / Q000188:drug therapy*
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor